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Summary 
Tumor necrosis factor (TNF) ot participates in the regulation of the acute-phase, immune, and 
inflammatory responses.  Target genes known to be transcriptionally activated by TNF-ot include 
the granulocyte (G)-colony-stimulating factor (CSF) gene, the granulocyte/macrophage (GM)- 
CSF gene, as well as the interleukin (IL) 6 gene. Functional nuclear factor (NF)-IL6 recognition 
sites have been identified in regulatory regions of these genes by transient transfection studies 
using deleted promoter constructs. In addition, NF-IL6 is known to form heterodimeric com- 
plexes with the NF-KB transcription factor, which is also engaged in the transcriptional regula- 
tion of these genes. The indispensable importance of NF-IL6 for regulating gene expression of 
proinflammatory cytokine genes in response to inflammatory stimuli in vivo remains, however, 
undear. We here report, by using both antisense (AS) oligodesoxyribonucleotide (ODN) and 
ribozyme (ILZ)-mediated specific elimination of NF-IL6 transcripts in human fibroblasts, that 
TNF-c~-induced synthesis of G-CSF, but not of GM-CSF or IL-6, is abolished in the absence 
of functional NF-IL6 in vivo. Both AS ODN and RZ targeting of the NF-IL6 transcript elimi- 
nate NF-IL6 protein, as shown in Western blot analysis and electrophoretic mobility shift assays. 
Similarly, fibroblasts exposed to either the AS NF-IL60DN  or the NF-IL6 RZ, but not to 
the sense or nonsense ODN or a mutated ribozyme, also failed to respond with functional activa- 
tion of NF-IL6 as assayed in transient transfection studies using heterologous promoter con- 
structs harboring the NF-IL6 recognition site. In contrast, protein synthesis, DNA-binding ac- 
tivity, and transcriptional activation capacity of the NF-KB transcription factor is not impaired 
upon exposure to either ODN  or RZ.  Fibroblasts that had been cultured in the presence of 
the AS NF-IL60DN or the NF-IL6RZ failed to synthesize G-CSF protein in response to TNF-cz, 
while TNF-cz-inducible transcription and release of GM-CSF and IL-6 was preserved. 
T 
he  nuclear  factor  (NF)-IL6  transcription  factor  was 
originally identified as an Ibl-inducible DNA-binding 
molecule mediating the transcription of the IL-6 gene in fi- 
broblasts (1). Besides coupling IL-1 to Ib6 expression, NF- 
IL6 was shown to also transmit other stimuli to the nucleus, 
including those delivered by LPS, TNF-ot, and IL-6 (for re- 
view see reference 2). More recently, it has been shown that 
NF-IL6 possesses functional sites in regulatory sequences of 
the ILl, IL-8, G-CSF, and GM-CSF genes as well as immu- 
noglobulin genes (2).  Molecular cloning of NF-IL6 has re- 
vealed its homology to the CCAAT enhancer binding protein 
(C-EBP), previously viewed as a hepatocyte-specific transcrip- 
tion factor (3). NF-IL6/C-EBP was also shown to be iden- 
tical to IL-6-induced DNA-binding protein, perceived to be 
crucial for IL-6-mediated activation of several acute phase re- 
sponse genes in the liver (4).  Based on these findings, NF- 
IL6 is thought to play a key role in the regulation of the 
acute-phase, immune, and inflammatory responses (2). Similar 
to NF-IL6, the transcription factor NF-gB is also recognized 
as a major regulatory molecule in the cellular response to 
infection and inflammation (for review see reference 5) and 
is also targeted by TNF-oe, IL-1, or LPS (5). Moreover, both 
transcription factors recognize binding sequences and exert 
transcriptional regulation control of the same target genes. 
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may cooperate to achieve transcriptional activation of their 
target genes not only by coordinated binding and transcrip- 
tional activation but also by functional interaction. NF-IL6 
has been shown to heterodimerize with the NF-KB transcrip- 
tion factor and thereby potentiates its transcriptional activation 
capacity (6, 7). Other studies have indicated that, despite the 
presence of functional NF-IL6 binding sites, transcriptional 
activation of several genes, including GM-CSF (8) and IL-6 
(9-11), may rely predominantly on the binding activity and 
transcriptional activation capacity of NF-~cB and various other 
transcription factors (12-14). However, the role of NF-IL6/ 
NF-KB heterodimers targeting the NF-KB recognition sequence 
has not yet been addressed.  In addition, previous studies have 
relied on transient transfection assays using deleted promoter- 
reporter gene constructs. Though these experiments are suit- 
able to identify functional domains within regulatory regions 
of single genes, they do not point to the nature of the pro- 
teins bound and mediating functional activation. To further 
elucidate the potential redundancy of NF-IL6 and NF-IcB in 
the regulation of cytokine gene expression and to clarifiy the 
functional  role  of  NF-IL6  in  mediating  transcriptional 
activation of cytokine genes, we have examined TNF-o~-in- 
ducible expression of three different target genes,  namely, 
G-CSF, GM-CSF, and IL-6. This analysis was performed on 
human fibroblasts that had been deprived of functional NF- 
IL6 by previous exposure to an antisense (AS) oligodesoxy- 
ribonucleotide (ODN) or a synthetic hammerhead ribozyme 
(RZ) directed to NF-IL6 transcripts. 
Materials and Methods 
Cell Culture.  The human embryonic lung fibroblast cell line 
FH 109 (15) was maintained in standard culture medium (SCM) 
R_PMI-1640 medium supplemented with 10% low-endotoxJn heat- 
inactivated FCS (Hazelton, Vienna, UT), 100 U/ml penicillin, 10 
/zg/ml streptomycin, and 2 mM L-glutamine (referred to as stan- 
dard culture medium [SCM]). FH 109 cells (106/ml) were exposed 
to recombinant human TNF-c~  (kindly provided  by G. Adolf, Bender 
KG, Vienna, Austria) in concentrations ranging from 1 to 150 U/ml. 
Western Blot Analysis.  Immunoprecipitation  and Western blot 
analysis were performed as previously described (16). Briefly, cells 
were lysed in RIPA buffer (20 mM Tris, pH 7.5, 150 mM NaC1, 
1 mM EDTA, 0.5% Deoxycholic acid (DOC), 1% Triton X-100, 
0.1% SDS) followed by centrifugation at 4~  for 20 min at 20,000 
g to remove  insoluble material. Lysates  were separated  by SDS-PAGE 
and transferred to Hybond C + membrane  (Amersham Buchler 
GmBH, Braunschweig, Germany). Filters were probed with a spe- 
cific anti-NF-IL6 antiserum (kindly provided by S. Akira, Osaka 
University, Osaka, Japan) or a specific mAb directed against the 
p65/rel A protein (Santa Cruz Biotechnology, Santa Cruz, CA), 
stripped, and then reprobed with a specific mAb directed against 
~2-microglobulin (Dianova, Hamburg,  Germany). 
AS ODN-mediated Elimination of NF-IL6.  AS experiments were 
performed essentially as previously described (16). An AS ODN 
corresponding to the ATG sequence of the human  NF-IL6 gene 
(5'-CAGC~GTTGCATGAACGCGG-3'), the corresponding sense 
(S) ODN (5'-CCGCGTTCATC~AACGCC'IG-3') and an unrelated 
nonsense  (NS)  ODN  (5'-CCAGAGAGGGCCCGTGTGGA-Y) 
with the same overall basepair compositon as the AS ODN were 
synthesized and stabilized by addition of thiosulfate groups, HPLC 
purified, and subsequently sequenced  (Genset, Paris, France). ODN 
were  complexed to  cationic  liposomes (Boehringer-Mannheim 
GmBH, Mannheim, Germany) as recommended by the manufac- 
turer and added to cell cultures in SCM every 12 h for up to 36 h. 
Uptake of labeled ODNs, intracellular ODN stability, and intra- 
cellular duplex formation of the AS ODN with its target sequence 
had been assessed and was identical as previously described in 
detail (16). 
RZ-mediated Elimination of NtZlL6.  A hammerhead RZ recog- 
nizing the UUC sequence at position  -3 to  -1 relative to the 
translation initiation  site (designated NF-IL6 RZ) was designed 
according to previously described criteria (17). The sequence of the 
NF-IL6 RZ is as follows: 5'-GCGTTGCATCUGAAGAGGCCG- 
AAAGGCCGAAAACGCGGGT-3' (the sequence  complementary 
to the NF-IL6 transcript is underlined). In addition, a mutated NF- 
IL6 RZ (RZm) carrying two base mutations (5'-GCGTTGCAT- 
CUaAAGAGGCCcAAAGGCCGAAAACGCGC~T-Y;  mutated 
bases are in lower case letters) (NF-IL6 RZmt) was also designed. 
The mutations introduced are known to interfere with the cata- 
lytic potential of hammerhead RZ (17). Both RZ harbor several 
chemical modifications according to previously published criteria 
(17). RZ  were  complexed to  cationic  liposomes (Boehringer- 
Mannheim GmBH) as recommended  by the manufacturer  and added 
to cell cultures in SCM every 12 h for up to 36 h. 
Preparation of Nuclear Proteins and Electrophoretic Mobility Shift 
Assays.  Electrophoretic mobility shift assays were performed es- 
sentially as previously described (16). Briefly, nudear extracts were 
prepared from FH 109 cells that had received (or not) liposome- 
complexed ODN or liposome-complexed RZ followed (or not) by 
exposure to TNF-a according to the Dignam  method.  Protein 
concentrations were determined by the Bradford assay. S and AS 
ODN (NF-IL6 S: 5'-TCGAGGACGTCATIGCACAATCTTAAT- 
AAG-3'; NF-IL6 AS 5'-TCGAACCTTATTAAGATTGTGCAA- 
TGAGT-3'; NF-IcB sense: 5'-TCGAGAGA GGC~ACTTTCCG- 
AGAGGC-Y; NF-KB antisense 5'-TCTCGGAAAGTCCCCTCT- 
CTCGAGGC-3', binding sites are underlined) corresponding to the 
NF-IL6-binding site of the IL-6 gene and the gB enhancer, respec- 
tively, were synthesized, annealed, and endlabeled. The endlabeled 
ODN (1 rig; "~10,000 cpm) were incubated with 10 #g nuclear 
proteins in an incubation buffer as previously described (10) for 
20 min at room temperature. For competition assays, incubation 
was performed in the presence of 25-fold molar excess  of  unlabeled 
double-stranded oligomers containing the NF-IL6 or NF-KB rec- 
ognition sequence or a mutated binding sequence. The reaction 
products were analyzed by electrophoresis in a 5% polyacrylamide 
gel followed by autoradiography. 
Transient Transfection  Assays.  Promoter constructs used for tran- 
sient transfection assays have been described elsewhere (10). Tran- 
sient transfections were performed by use of commercially avail- 
able liposomes (Boehringer Mannheim GmBH) as detailed by the 
manufacturer. Cells were cultured in  the presence of liposome- 
complexed DNA for 24 h, split, and cultured in the presence or 
absence of TNF-c~ (100 U/ml) for an additional 24 h, followed by 
analysis of  human growth hormone (hGH) activity in cell-free  cul- 
ture supernatants using a hGH-specific enzyme  immunoassay (Eu- 
rogenetics, Tessenderio, Belgium). 
~e  Transcription  PCR and Southern Blot Analysis.  RNAprep- 
aration and reverse transcription  (RT) PCR reactions were per- 
formed as previously described (17). Primers used were as follows. 
G-CSF primers: S, 5'-CAGAGCCTGCTGC'IL-TIG-3';  AS, 5'-AGC- 
AGTCAAAGGGGATGAC-Y;  GM-CSF primers: S, 5'-CAGAGC- 
CTGCTGCTCTTG-3'; AS, 5'-AGCAGTCAAAGGGGATGAC-3'; 
794  TNF-mediated  Expression of G-CSF Requires NF-IL6 IL-6 primers: S, 5'-ACAAATTCGGTACATCCTCG-3'; AS, 5'-ATG- 
AGTTGTCATGTC  CTGCA-3';  32-microglobulin  primers:  S, 
5'-CCAGCAGAGAATC~AAAGTC-3'; AS, 5'-GA.W~'/GCTTAC- 
ATGTCT-3'. One fifth of each RT-PCR reaction mixture was run 
on 1% agarose gels, followed by Southern blotting and hybridiza- 
tion to  specific cDNA probes. 
Determination  of Cytokine Concentrations in Cell-free Culture Super- 
natants.  Concentrations of G-CSF, GM-CSF, or IL-6 were deter- 
mined in cell-free culture supernatants  by commercially availabe 
ELISA assays (R&D Systems, Minneapolis, MN [II,-6]; Amgen Bio- 
chemicals, Thousand Oaks, CA [G-CSF]; Medical Resources Ltd., 
Darlington,  Australia [GM-CSF]). 
Results 
Upon exposure to TNF-c~, FH 109 fibroblasts responded 
with enhanced synthesis of both the NF-IL6 and the NF-KB 
transcription  factor (Fig. 1). The capacity of TNF-c~ to pro- 
mote synthesis of NF-IL6 or NF-KB was dose dependent in 
the range of 1-100 U/ml and also time dependent (data not 
shown).  Maximum protein accumulation  was observed at a 
concentration of 100 U/m1 after 6 h.  Therefore,  this  dose 
and time point were chosen for further experiments.  Cells 
that had received NF-IL6-specific liposome-complexed  AS 
ODN for 24 h failed, however, to display the NF-IL6 pro- 
tein after TNF-c~ exposure, while the level of NF-KB protein 
remained unchanged.  In contrast,  exposure to S or NS ODN 
did not interfere with TNF-o~-inducible  accumulation  of ei- 
ther transcription  factor.  Likewise, cells that  had been ex- 
posed to liposome-complexed  NF-IL6-specific RZ failed to 
produce NF-IL6 upon exposure to TNF-ot, while cells that 
had received an RZm continued to produce NF-IL6 protein 
in response  to TNF-ot. 
In line with these  findings,  we also failed to detect  en- 
hanced NF-IL6-binding activity after TNF-ot stimulation of 
cells that had previously  been treated with liposome-complexed 
AS  ODN  or  liposome-complexed  RZ,  while  liposome- 
complexed  S or NS ODN and liposome-complexed  RZm 
failed to interfere with TNF-ol to promote NF-IL6-binding 
activity. The ability of the NF-KB protein to bind DNA in 
response to TNF-ot stimulation was not impeded by either 
AS, S, or NS ODN nor by the active or inactive ribozyme 
(Fig. 2). 
The next set of experiments aimed at elucidating the func- 
tional activation of both NF-IL6 and NF-KB by TNF-ot via 
transient  transfection  assays. FH 109 cells that had (or not) 
been exposed  to liposome-complexed  ODN or liposome- 
complexed RZ were transiently  transfected  with heterolo- 
gous reporter gene constructs harboring the NF-IL6- or the 
NF-KB-binding  sequence followed by TNF-ot stimulation. 
While functional  activation  of the NF-KB construct in re- 
sponse to TNF-c~ was unaffected under all experimental con- 
ditions,  the functional  activation  of the NF-IL6 construct 
was completely abolished in cells that had previously received 
liposome-complexed  AS ODN or liposome-complexed  ac- 
tive RZ (Fig.  3). 
Among the genes known to be induced by TNF-ot in fi- 
Figure  1.  NF-IL6 AS ODN or NF-IL6-directed  RZ prevent TNF-~-in- 
ducible accumulation of NF-IL6 in fibroblasts. FH 109 cells were cul- 
tured in the presence or absence of liposomes (LS), liposome-complexed 
AS, S, or NS ODN or to liposome-complexed NF-IL6 RZ or NF-IL6 
RZm for 24 h  and then exposed to TNF-ot (100 U/ml) for 6 h. Cell 
lysates were separated  and analyzed by immunoblotting as detailed in 
Materials and Methods for expression of NF-IL6 and p65 NF-KB. Shown 
is one representative experiment. Two additional experiments gave com- 
parable results. 
Figure  2.  NF-IL6 AS ODN and NF-IL6 RZ prevent enhanced  NF- 
IL6 binding activity after TNF-c~ stimulation of fibroblasts.  FH 109 cells 
were cultured in the presence  or absence of liposomes (LS),  liposome- 
complexed AS, S, or NS ODN  or liposome-complexed NF-IL6 RZ or 
NF-IL6 RZm for 24 h and then exposed to TNF-ot (100 U/ml) for 1 h. 
Cell lysates were prepared and analyzed for binding activity by use of 
hbeled double-stranded oligomers containing the NF-IL6 (/eft)  or the NF-KB 
(right) recognition sequence. Competition assays were performed in the 
presence of 25-fold molar excess of double-stranded oligomers harboring 
the respective binding site (wt) or a mutated binding sequence (rot). Shown 
is one representative experiment. One additional experiment gave iden- 
tical results. 
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Figure  3.  NF-IL6 AS ODN and NF-IL6 RZ prevent functional  acti- 
vation of NF-IL6 by TNF-(x in fibroblasts.  FH 109 fibroblasts were cul- 
tured in the presence or absence of liposomes (LS), liposome-complexed 
AS, S, or NS ODN (A) or liposome-complexed  NF-IL6 RZ or NF-IL6 
RZm (B) for 24 h and then transiently  transfected with heterologous  pro- 
moter constructs  harboring  the NF-IL6 (left) or the NF-KB (right) binding 
sequences 5' of the herpes thymidine kinase (HTK) promoter linked to 
the hGH gene as a reporter. Transfectants  were maintained  in the pres- 
ence of liposomes,  liposome-complexed  ODN, or liposome-complexed 
RZ for an additional  24 h, split,  and either left untreated or exposed to 
TNF-(x (100 U/ml) for an additional  12 h. Thereafter, hGH activity was 
determined in cell-free culture supernatants  with a commercially available 
EIA assay. Transfectants  harboring  the control construct  (pTKGH) failed 
to respond to TNF-a with enhanced hGH synthesis under all experimental 
conditions  (not shown).  I-3, SCM; [],  TNF-a. 
A.  & 
0  ~  i  i  i  i  i 
ZS  AS  AtS  S  ZS  RZ  RZm 
]  :g  200  ~:  200 
{.,)  g 
0  /  ,  ,  ,  ,  0  ,  ,  , 
LS  AS  NS  S  LS  RZ  RZrn 
~  ~o 
200  ~  2 
0  i 
LS  AS  /VS  S  LS  RZ  RZrn 
Figure 4.  NF-IL6 AS ODN and NF-IL6 RZ interfere with the ability 
of TNF-ot to induce release of G-CSF, but not GM-CSF or IL-6 by fibro- 
blasts. FH 109 cells were cultured in the presence or absence of liposomes 
Figure  5.  NF-IL6 AS ODN and NF-IL6 RZ interfere with the ability 
of TNF-a to induce G-CSF, but not GM-CSF or IL-6 mRNA, in fibro- 
blasts. FH 109 cells were cultured in the presence or absence of liposomes 
(LS), liposome-complexed  AS, S, or NS ODN, or liposome-complexed 
NF-IL6 RZ (RZ)  or NF-IL6 RZm (RZra) for 24 h and then exposed 
to TNF-ot (100 U/ml) for an additional  4 h. Thereafter,  cellular RNA 
was prepared and analyzed for the expression of G-CSF, GM-CSF, IL-6, 
and 32-microglobulin  by RT-PCR and Southern  blotting analysis. 32" 
microglobulin was coamplified in all reactions to control for comparable 
amounts  of RNA subjected to RT-PCR analysis and allow internal stan- 
dardization.  Shown is one representative  experiment;  one additional ex- 
periment gave identical  results. 
broblasts are G-CSF, GM-CSF, and Ib6. Pilot experiments, 
not shown here, had indicated that TNF-a time dependently 
enhanced the release of G-CSF, GM-CSF, or II.,6 in FH 109 
cells, which was maximal  at 24 h (15 and Kiehntopf,  M., 
F. Herrmann, and M. A. Brach, unpublished data). This time 
point was therefore chosen for further experiments. TNF- 
a-mediated release of G-CSF was completely relieved in cells 
that had been exposed to liposome-complexed  AS ODN or 
liposome-complexed  RZ, while TNF-a-mediated release of 
GM-CSF or Ib6 was unaffected by this procedure (Fig. 4). 
Cells that had received liposome-complexed  S or NS ODN 
or liposome-complexed  RZm responded to TNF-a with en- 
hanced release of G-CSF, GM-CSF, and II.-6. 
These genes harbor in their promoter both NF-IL6- and 
NF-gB-binding sites. Functional activation of all three genes 
involving either NF-IL6 or NF-xB has previously  been reported 
(LS), liposome-complexed AS, S, or NS ODN (A) or liposome-complexed 
NF-IL6 RZ or NF-IL6 RZm (B) for 24 h and then exposed to TNF-~x 
(100 U/ml) for an additional 12 h. Thereafter,  cell-free supernatants were 
assayed for G-CSF, GM-CSF, and IL-6 by use of a commercially available 
ELISA. Data are shown as mean value _+ SD of three independent  experi- 
ments,  nd; not detectable.  [],  SCM; [],  TNF-cz. 
796  TNF-mediated Expression  of G-CSF  Requires  NF-IL6 (8-14,  18). We have therefore also analyzed the expression 
of G-CSF, GM-CSF, and I1.6 in response to TNF-ol in FH 
109 cells that had (or not) received  liposome-complexed  ODN 
or NF-IL6-directed liposome-complexed  RZ by RT-PCR and 
Southern blotting (Fig. 5). In previous experiments, TNF-ot 
was shown to time dependently induce mRNA accumula- 
tion of G-CSF, GM-CSF, and I1.6 in FH 109 cells, with max- 
imum mRNA accumulation seen after 4 h of exposure (15 
and Kiehntopf, M., F. Herrmann, and M. A. Brach, unpub- 
lished data). This time point was therefore chosen for fur- 
ther experimentation. FH 109 cells responded to TNF-ot with 
enhanced mRNA accumulation of G-CSF, GM-CSF, or I1.6 
when previously exposed to liposome-complexed  S or NS 
ODN or to lipsosome-complexed RZm. TNF-c~-mediated 
accumulation of G-CSF mRNA was completely abolished 
in cells that had received liposome-complexed AS ODN or 
liposome-complexed RZ. In contrast, TNF-ot-mediated ac- 
cumulation of  both 11-6 or GM-CSF mRNA was unaffected 
by the presence of the AS ODN or the NF-IL6-directed RZ. 
These findings indicate that TNF-ot-mediated regulation of 
G-CSF gene expression  requires NF-IL6, while TNF-ot-medi- 
ated regulation of GM-CSF  or I1.6 expression also occurs 
in its absence. 
Discussion 
We have designed an NF-IL6-specific  AS ODN and an 
NF-IL6-specific RZ. Both the AS ODN and the RZ were 
incorporated into human FH 109 fibroblasts by liposomal 
transfer (not shown). The specificity of NF-IL6 elimination 
was shown at the protein level  by Western blot analysis, DNA 
binding studies, and functional assays using transient trans- 
fection assays of heterologous promoter constructs. This model 
system allowed investigation  of the functional role of NF- 
IL6 in regulating fibroblast gene expression of G-CSF, GM- 
CSF, and I1.6 in response to TNF-ot stimulation.  We show 
that TNF-ot-mediated induction of G-CSF requires functional 
NF-IL6. In contrast, TNF-oe-induced activation of GM-CSF 
and I1.6 gene expression also occurs in the absence of NF- 
IL6 and thus may demand the presence of the NF-KB mole- 
cule or other transcription  factors. This view is supported 
by previous transient transfection assays indicating that dele- 
tion of the NF-xB recognition site interfered with inducible 
transcriptional activation of the I1.6 gene (9-11), while tran- 
scriptional  activation  of the GM-CSF  gene required both 
NF-xB and other transcription factors (8, 12-14). Several  lines 
of evidence have indicated that transcriptional  activation of 
the G-CSF promoter may involve the NF-IL6 transcription 
factor (14, 18-21). The mouse G-CSF promoter contains a 
NF-~B recognition sequence (21), which is, however, not rec- 
ognized by nuclear proteins  obtained  from mouse macro- 
phages. Although the p65 subunit of the NF-xB transcription 
factor may target the G-CSF promoter in human cells, it 
requires the NF-IL6  protein for binding (18). We further 
support  and extend these findings by demonstrating that 
TNF-o~-mediated  transcriptional activation of the G-CSF gene 
in vivo in fibroblasts strictly depends on the NF-IL6 protein 
and cannot be achieved  by NF-KB or other transcription factors 
including members of the C-EBP family in the absence of 
NF-IL6. 
Regulation of both GM-CSF and II-6 gene expression in 
response to various extracellular stimuli has been extensively 
studied (8-14),  and data have been accumulated to suggest 
that the NF-KB recognition sequence is crucial for transcrip- 
tional activation of the I1-6 gene, despite the presence of an 
NF-IL6-binding sequence. However, the nature of the pro- 
teins binding to the NF-xB recognition site has not been pre- 
cisely characterized. NF-KB can contact its recognition site 
both as a p50/p65  heterodimer or as complexes consisting 
of both NF-~B and NF-IL6 (6, 7). Therefore, NF-IL6 may 
participate in I1.6 gene activation, engaging the NF-KB rec- 
ognition sequence. While the NF-KB site within the GM- 
CSF promoter is functional, transcriptional activation of the 
GM-CSF gene has also been shown to rely on various other 
transcription  factors, including AP-1 (8,  12-14). Our data 
provide conclusive evidence to suggest that despite the pres- 
ence of  functional NF-IL6-binding sequences  in both the GM- 
CSF and IL-6 promoter, transcriptional activation of  both genes 
in response to TNF-a does not require NF-IL6. 
The cytokines under investigation in this study exert unique 
biological functions: GM-CSF is a known activator of mac- 
rophages and APC, IL-6 plays a major role in initiating the 
acute phase response in the liver, and G-CSF primarily stimu- 
lates function and survival of neutrophils and their precursors, 
but does not target mononuclear phagocytes (22). Based on 
their distinct in vivo functions, it is reasonable to allow dis- 
tinct transcription  factors to govern the expression of their 
genes. DNA-binding activity of NF-IL6 is enhanced in vivo 
after threonine phosphorylation through the microtubule- 
associated protein (MAP) kinase and appears therefore to be 
controlled by an activated ras and c-raf-1 protein (23). Taken 
together with these findings, our data demonstrate that TNF- 
a-mediated activation of MAP kinase (24) leads to activa- 
tion of the G-CSF gene by engaging the NF-IL6 transcrip- 
tion factor. 
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